Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

UK must embrace genomics or face medicines “dark age”

Life sciences minister George Freeman calls for NHS to embrace new data and technology

Webinar series: E-detailing content that works

E-detailing and closed loop marketing is too often seen as a technical issue rather than a creative one. Yet to get the most from the technology you need to have...

Anthill Agency

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

- PMLiVE

PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

Cancer drug could be approved in the US within months

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Communiqué Awards 2015 now open for entries

Health communications programme sees a number of category changes this year

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

- PMLiVE

The problem with pills

Conventional solid dosage forms have failed to keep pace with modern consumers’ evolving demands

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

- PMLiVE

US seeking price cuts for Medicare drugs

White House proposes allowing Medicare Part D to haggle with pharma companies for discounts

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links